Background
Materials and methods
Study cohorts
KANK1 transcriptomic data
KANK1 protein expression
KANK1 protein cohort
Immunohistochemistry (IHC)
Scoring of KANK1 protein expression
Statistical analysis
Results
Clinicopathological significance of KANK1 mRNA expression
Parameters | METABRIC cohort | TCGA cohort | ||||
---|---|---|---|---|---|---|
Low KANK1 | High KANK1 | p value | Low KANK1 | High KANK1 | p value | |
N (%) | N (%) | N (%) | N (%) | |||
Tumour size | ||||||
≤ 2.0 cm | 407 (47) | 452 (53) | 0.033 | 112 (47) | 127 (53) | 0.29 |
>2.0 cm | 575 (52) | 526 (48) | 315 (51) | 300 (49) | ||
Nodal stage | ||||||
Negative | 502 (49) | 533 (519) | 0.14 | 193 (45) | 233 (55) | 0.007 |
Positive | 487 (52) | 451 (48) | 231 (55) | 192 (45) | ||
Lymphovascular invasion | ||||||
Negative | 437 (47) | 493 (53) | 0.005 | 258 (46) | 301 (54) | 0.002 |
Positive | 344 (54) | 291 (45) | 169 (57) | 126 (43) | ||
Histological grade | ||||||
Grade 1 and 2 | 433 (46) | 507 (54) | 0.001 | 229 (49) | 235 (51) | 0.62 |
Grade 3 | 513 (54) | 439 (46) | 180 (51) | 172 (49) | ||
Oestrogen receptor | ||||||
Negative | 211 (44) | 263 (56) | 0.007 | 66 (35) | 119 (65) | < 0.001 |
Positive | 779 (52) | 727 (48) | 345 (54) | 294 (46) | ||
Progesterone receptor | ||||||
Negative | 482 (51) | 458 (49) | 0.3 | 119 (44) | 153 (56) | 0.018 |
Positive | 508 (49) | 532 (51) | 288 (53) | 258 (47) | ||
Human epidermal growth factor receptor 2 | ||||||
Negative | 817 (47) | 916 (53) | < 0.001 | 254 (45) | 313 (55) | < 0.001 |
Positive | 173 (70) | 74 (30) | 94 (71) | 39 (29) |
Gene names | METABRIC cohort | TCGA cohort | ||
---|---|---|---|---|
Correlation value | p value | Correlation value | p value | |
CDH1 | 0.052 | 0.022 | 0.147 | < 0.001 |
CDH2 | − 0.074 | 0.001 | − 0.035 | 0.31 |
TGFB1 | − 0.043 | 0.054 | − 0.157 | < 0.001 |
TWIST2 | 0.146 | < 0.001 | − 0.004 | 0.9 |
TWIST1 | 0.024 | 0.29 | − 0.44 | 0.2 |
ZEB2 | 0.146 | < 0.001 | 0.061 | 0.075 |
ZEB1 | 0.008 | 0.73 | 0.016 | 0.65 |
SLUG | 0.193 | < 0.001 | 0.143 | < 0.001 |
SNAIL | 0.014 | 0.54 | 0.061 | 0.075 |
NFKB1 | 0.069 | 0.002 | 0.057 | 0.095 |
LLGL2 | − 0.237 | 0.002 | − 0.118 | < 0.001 |
GSK3B | − 0.193 | < 0.001 | 0.094 | 0.006 |
CRUMBS | − 0.092 | < 0.001 | 61 | 0.075 |
CTNNB1 | 0.206 | < 0.001 | 0.222 | < 0.001 |
KANK1 protein expression
Parameters | KANK1 protein expression | ||
---|---|---|---|
Low | High | p value | |
N (%) | N (%) | ||
Tumour size | |||
≤ 2.0 cm | 382 (47.9) | 415 (52.1) | 0.012 |
> 2.0 cm | 290 (55.0) | 237 (45.0) | |
Nodal stage | |||
Negative | 408 (50.0) | 408 (50.0) | 0.46 |
Positive | 263 (52.1) | 242 (47.9) | |
Lymphovascular invasion | |||
Negative | 461 (49.5) | 471 (50.5) | 0.15 |
Positive | 211 (53.8) | 181 (46.2) | |
Histological grade | |||
Grade 1 and 2 | 360 (51.6) | 337 (48.4) | 0.49 |
Grade 3 | 312 (49.8) | 315 (50.2) | |
Nottingham Prognostic Index | |||
Good prognostic group | 198 (47.4) | 220 (52.6) | 0.22 |
Moderate prognostic group | 361 (52.8) | 323 (47.2) | |
Poor prognostic group | 112 (51.4) | 106 (48.6) | |
Oestrogen receptor | |||
Negative | 133 (47.3) | 148 (52.7) | 0.2 |
Positive | 540 (51.7) | 505 (48.3) | |
Progesterone receptor | |||
Negative | 276 (49.6) | 281 (50.4) | 0.47 |
Positive | 393 (51.6) | 369 (48.4) | |
Human epidermal growth factor receptor 2 | |||
Negative | 599 (52.6) | 539 (47.4) | 0.00074 |
Positive | 74 (39.4) | 114 (60.6) | |
Triple negative breast cancer | |||
Negative | 571 (51) | 549 (49) | |
Positive | 102 (49) | 104 (51) | 0.699 |
Factors | BCSS | TDDM | ||||
---|---|---|---|---|---|---|
Hazard Ratio | 95% CI | p value (< 0.05) | Hazard ratio | 95% CI | p value (< 0.05) | |
KANK1 expression | 1.4 | 1.072–1.786 | 0.0013 | 1.3 | 1.02–1.64 | 0.033 |
Tumour size | 0.78 | 0.59–1.02 | 0.065 | 0.68 | 0.53–0.88 | 0.003 |
Tumour grade | 1.62 | 1.26–2.08 | < 0.0001 | 1.35 | 1.08–1.68 | 0.008 |
Tumour stage | 1.78 | 1.50–2.13 | < 0.0001 | 1.65 | 1.40–2.00 | < 0.0001 |
Lymophvascular invasion | 0.54 | 0.41–0.71 | < 0.0001 | 0.55 | 0.43–0.88 | < 0.0001 |
ER status | 1.11 | 0.79–1.57 | 0.544 | 0.99 | 0.71–1.38 | 0.95 |
PR status | 0.57 | 0.42–0.78 | < 0.0001 | 0.68 | 0.50–0.88 | 0.004 |
HER2 expression | 0.76 | 0.56–1.04 | 0.09 | 0.67 | 0.50–0.90 | 0.007 |